Plain-English translation of NCT07179692 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lung Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new treatment called CEA-targeted CAR-T therapy, which uses your own immune cells that are grown in a laboratory and trained to recognize and attack cancer cells. Researchers will give you these modified cells through one of three methods—injection into a vein, into the space around your lungs, or into your abdomen—to see if this treatment can help people with advanced cancers like lung, stomach, colon, or pancreatic cancer that have not responded to standard treatments.
Currently, many people with advanced cancers run out of effective treatment options after standard chemotherapy and other therapies stop working. This medication represents a newer approach that harnesses the body's own immune system to target and destroy cancer cells, offering hope for patients who have limited alternatives.
You likely qualify if…
You likely don't qualify if…
You will first have blood drawn so your immune cells can be collected and modified in a laboratory over several weeks. Once the cells are ready, you will return to receive an infusion of the treatment through one of three methods (a vein injection, injection around the lungs, or injection into the abdomen). After that, you will have regular follow-up visits with blood tests and imaging scans to monitor how well the treatment is working and any side effects you may experience.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China